About RIGImmune Inc.

RIGImmune’s mission is to create a new class of therapies that harness the body’s own immune system to better fight off viral diseases and cancer.

RIGImmune is developing best-in-class host targeted immune activating therapies utilizing novel Stem Loop RNA (SLRs) molecules. The SLRs are formulated as broad-spectrum antivirals and immuno-oncology therapeutics in proprietary non-LNP tissue-targeted delivery technology.

RIGImmune has also developed an advanced respiratory drug delivery capability with a proprietary platform formulation technology for specific delivery of mRNA, DNA, and oligonucleotides of diverse size and structure without the need for lipid nanoparticle (LNP) encapsulation.

Our lead candidate RIG-101 has an initial focus on pre- and post-exposure prophylaxis of respiratory viral infections in high-risk patient populations and as a broad-spectrum vaccine adjuvant for respiratory diseases with high unmet clinical needs.

Our core technology is designed to target a pattern recognition receptor called cytosolic RNA RIG-I, which plays a critical role as sentinel in activation of the innate immune system. RIG-I is key to our body’s natural defense against viral infection. When viral RNA enters our cells, the cells’ natural defense responds rapidly by activating sensor proteins that trigger RIG-I and our innate immune system.

Our SLRs are designed to mimic the physiological double-stranded viral RNA ligands for RIG-I that are released during viral infection. They act as rapid, specific and potent activators of retinoic acid-inducible gene I (RIG-I), our first line of defense as a cytosolic innate immune sensor. The innate immune system utilizes host encoded nucleic acid sensors known as pattern recognition receptors (PRRs). RIG-I is one such PRR that mediates viral RNA recognition and initiates front line anti-viral defense through Interferon-1 dependent and independent mechanisms.

RIGimmune’s novel SLRs harness and control RIG-I, enabling the patients’ own immune system to fight diseases and provide rapid improvement and sustained effects.

Our Story Begins with Transformative Research

Our co-founders are international leaders in immune response and defense, holding insights that have allowed them to advance RIGImmune’s novel platform. Co-founder Anna Marie Pyle, PhD, and colleagues discovered the RIG-I family and designed stem loop RNA therapeutics for selective targeting of RIG-I. Co-founder Akiko Iwasaki, PhD, is renowned for her work with mechanisms of immune defense against viruses at the mucosal surfaces, and the development of mucosal vaccine strategies. Together co-founders Anna Marie Pyle, PhD, and Akiko Iwasaki, PhD, are developing SLRs as antitumor and anticancer compounds.

In 2022, RIGImmune acquired SubIntro, a UK biotechnology company progressing antivirals formulations for local mucosal and inhalation delivery. Subintro, Inc., co-founded by the three notable and highly successful respiratory drug developers, Kaz Ito, PhD, DVM and Garth Rapeport, MD, and Jag Shur, PhD, brought together expertise in development and delivery of respiratory therapies.

Subintro had developed proprietary formulations that were the missing piece needed for RIG-101’s intranasal delivery. The expanded team rapidly brought together the multi-dimensional approach needed to create RIG-101 which is advancing toward a targeted clinical start in late 2024.

Management Team

Susan Sobolov, PhD

President, RIGImmune Inc.

Read Bio

Radhakrishnan (Kris) Iyer, PhD

Chief Scientific Officer, RIGImmune Inc.

Read Bio

Garth Rapeport, MD

Chief Development Officer, RIGImmune Inc.

Read Bio

Jag Shur, PhD

Chief Technical Officer, RIGImmune Inc.

Read Bio

Board of Directors

Jesal Shah

Head of Strategy, Alembic Pharmaceuticals, Ltd.

Read Bio

Tom Smart, MBA

CEO & Board Chair, Gravitas Therapeutics, Inc.

Read Bio

Monica Zhou, PhD

Investment Manager, Lifespan Investments

Read Bio

Martin Driscoll, Board Chair

CEO & Director, OncoNano Medicine, Inc.

Read Bio

Nihal Sinha

Partner, F-Prime

Read Bio

Scientific Advisory Board

Prof. Anna Marie Pyle, PhD

Co-Founder & Scientific Advisor

Read Bio

Prof. Akiko Iwasaki, PhD

Co-Founder & Scientific Advisor

Read Bio

Prof. Kazuhiro Ito, PhD

Scientific Advisor

Read Bio